ACTC CEO Gary Rabin recently presented at the 14th Annual Rodman & Renshaw Global Investment Conference.
As one of the few companies engaged in embryonic stem cell research, ACTC
has generated significant interest among investors.
However, the field of stem cell research remains controversial.
commented on U.S. Appeals' Court's dismissal ruling in case challenging federal funding of embryonic stem cell research.
CEO Rabin said that the court ruling should be of considerable benefit to the company and its embryonic stem cell-based clinical programs.
said that the ruling effectively removes major speed bumps for the National Institutes of Health
in terms of approving the several stem cell lines that ACTC
has submitted for their consideration for funding.
also said that the ruling removes a great deal of ambiguity that has hampered legislative attempts to provide an efficient mechanism for federal funding of hESC research.
added that the path for legislators to enact such legislation has now been cleared and in that case ACTC
is optimistic that there could be encouraging new developments in the legislative arena, as well, in coming months.